Literature DB >> 23197820

Specimen collection for induced pluripotent stem cell research: harmonizing the approach to informed consent.

Justin Lowenthal1, Scott Lipnick, Mahendra Rao, Sara Chandros Hull.   

Abstract

Induced pluripotent stem cells (iPSCs) have elicited excitement in both the scientific and ethics communities for their potential to advance basic and translational research. They have been hailed as an alternative to derivation from embryos that provides a virtually unlimited source of pluripotent stem cells for research and therapeutic applications. However, research with iPSCs is ethically complex, uniquely encompassing the concerns associated with genomics, immortalized cell lines, transplantation, human reproduction, and biobanking. Prospective donation of tissue specimens for iPSC research thus requires an approach to informed consent that is constructed for this context. Even in the nascent stages of this field, approaches to informed consent have been variable in ways that threaten the simultaneous goals of protecting donors and safeguarding future research and translation, and investigators are seeking guidance. We address this need by providing concrete recommendations for informed consent that balance the perspectives of a variety of stakeholders. Our work combines analysis of consent form language collected from investigators worldwide with a conceptual balancing of normative ethical concerns, policy precedents, and scientific realities. Our framework asks people to consent prospectively to a broad umbrella of foreseeable research, including future therapeutic applications, with recontact possible in limited circumstances. We argue that the long-term goals of regenerative medicine, interest in sharing iPSC lines, and uncertain landscape of future research all would be served by a framework of ongoing communication with donors. Our approach balances the goals of iPSC and regenerative medicine researchers with the interests of individual research participants.

Entities:  

Mesh:

Year:  2012        PMID: 23197820      PMCID: PMC3659701          DOI: 10.5966/sctm.2012-0029

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  116 in total

1.  What makes clinical research ethical?

Authors:  E J Emanuel; D Wendler; C Grady
Journal:  JAMA       Date:  2000 May 24-31       Impact factor: 56.272

Review 2.  Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering.

Authors:  Kevin K Parker; Donald E Ingber
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-08-29       Impact factor: 6.237

3.  Stem cells from skin cells: the ethical questions.

Authors:  Insoo Hyun
Journal:  Hastings Cent Rep       Date:  2008 Jan-Feb       Impact factor: 2.683

Review 4.  The bioethics of stem cell research and therapy.

Authors:  Insoo Hyun
Journal:  J Clin Invest       Date:  2010-01       Impact factor: 14.808

5.  Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells.

Authors:  Joyce E Ohm; Prashant Mali; Leander Van Neste; David M Berman; Liang Liang; Kurinji Pandiyan; Kimberly J Briggs; Wei Zhang; Pedram Argani; Brian Simons; Wayne Yu; William Matsui; Wim Van Criekinge; Feyruz V Rassool; Elias Zambidis; Kornel E Schuebel; Leslie Cope; Jonathan Yen; Helai P Mohammad; Linzhao Cheng; Stephen B Baylin
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

6.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency.

Authors:  Frederick Anokye-Danso; Chinmay M Trivedi; Denise Juhr; Mudit Gupta; Zheng Cui; Ying Tian; Yuzhen Zhang; Wenli Yang; Peter J Gruber; Jonathan A Epstein; Edward E Morrisey
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

7.  Induced pluripotent stem cells generated without viral integration.

Authors:  Matthias Stadtfeld; Masaki Nagaya; Jochen Utikal; Gordon Weir; Konrad Hochedlinger
Journal:  Science       Date:  2008-09-25       Impact factor: 47.728

Review 8.  Technical challenges in using human induced pluripotent stem cells to model disease.

Authors:  Krishanu Saha; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

9.  Somatic coding mutations in human induced pluripotent stem cells.

Authors:  Athurva Gore; Zhe Li; Ho-Lim Fung; Jessica E Young; Suneet Agarwal; Jessica Antosiewicz-Bourget; Isabel Canto; Alessandra Giorgetti; Mason A Israel; Evangelos Kiskinis; Je-Hyuk Lee; Yuin-Han Loh; Philip D Manos; Nuria Montserrat; Athanasia D Panopoulos; Sergio Ruiz; Melissa L Wilbert; Junying Yu; Ewen F Kirkness; Juan Carlos Izpisua Belmonte; Derrick J Rossi; James A Thomson; Kevin Eggan; George Q Daley; Lawrence S B Goldstein; Kun Zhang
Journal:  Nature       Date:  2011-03-03       Impact factor: 49.962

10.  Direct cell reprogramming is a stochastic process amenable to acceleration.

Authors:  Jacob Hanna; Krishanu Saha; Bernardo Pando; Jeroen van Zon; Christopher J Lengner; Menno P Creyghton; Alexander van Oudenaarden; Rudolf Jaenisch
Journal:  Nature       Date:  2009-11-08       Impact factor: 49.962

View more
  21 in total

1.  The DISCUSS Project: induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: points to consider.

Authors:  Geoffrey P Lomax; Sara Chandros Hull; Justin Lowenthal; Mahendra Rao; Rosario Isasi
Journal:  Stem Cells Transl Med       Date:  2013-08-29       Impact factor: 6.940

Review 2.  Concise review: making and using clinically compliant pluripotent stem cell lines.

Authors:  Melissa K Carpenter; Mahendra S Rao
Journal:  Stem Cells Transl Med       Date:  2015-02-26       Impact factor: 6.940

3.  Ethics and policy issues for stem cell research and pulmonary medicine.

Authors:  Justin Lowenthal; Jeremy Sugarman
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

4.  Harmonizing standards for producing clinical-grade therapies from pluripotent stem cells.

Authors:  Peter W Andrews; Joy Cavagnaro; Joy Cavanagro; Robert Deans; Ellen Feigal; Ellen Feigel; Ed Horowitz; Armand Keating; Mahendra Rao; Marc Turner; Ian Wilmut; Shinya Yamanaka
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

Review 5.  Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative.

Authors:  Leonard A Levin; Joan W Miller; Donald J Zack; Martin Friedlander; Lois E H Smith
Journal:  Ophthalmology       Date:  2017-03-29       Impact factor: 12.079

6.  Patients' attitudes toward the donation of biological materials for the derivation of induced pluripotent stem cells.

Authors:  Ishan Dasgupta; Juli Bollinger; Debra J H Mathews; Neil M Neumann; Abbas Rattani; Jeremy Sugarman
Journal:  Cell Stem Cell       Date:  2014-01-02       Impact factor: 24.633

7.  Broad Consent for Research on Biospecimens: The Views of Actual Donors at Four U.S. Medical Centers.

Authors:  Teddy D Warner; Carol J Weil; Christopher Andry; Howard B Degenholtz; Lisa Parker; Latarsha J Carithers; Michelle Feige; David Wendler; Rebecca D Pentz
Journal:  J Empir Res Hum Res Ethics       Date:  2018-02-01       Impact factor: 1.742

8.  Broad versus blanket consent for research with human biological samples.

Authors:  David Wendler
Journal:  Hastings Cent Rep       Date:  2013 Sep-Oct       Impact factor: 2.683

9.  Developing cellular therapies for retinal degenerative diseases.

Authors:  Kapil Bharti; Mahendra Rao; Sara Chandros Hull; David Stroncek; Brian P Brooks; Ellen Feigal; Jan C van Meurs; Christene A Huang; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-26       Impact factor: 4.799

10.  Meeting report: using stem cells for biological and therapeutics discovery in mental illness, April 2012.

Authors:  David M Panchision
Journal:  Stem Cells Transl Med       Date:  2013-02-13       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.